Evidence Impact on Biologics Confidence for Psoriasis
This trial will study whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.
Monoclonal Antibodies
Ustekinumab for Psoriasis
This trial is looking to see if researchers can predict which psoriasis drugs will work for individual patients by looking at markers or gene patterns. Participants will try two different drugs for 8 weeks at a time and have their skin monitored for improvement.
Monoclonal Antibodies
Guselkumab for Psoriasis
This trial tests Guselkumab, a medication that reduces inflammation, on high-risk psoriasis patients to prevent them from developing Psoriatic Arthritis. The drug works by blocking IL-23, a molecule that causes inflammation. Guselkumab is approved for treating moderate-to-severe plaque psoriasis.
Popular Filters
Trials for Plaque Psoriasis Patients
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Plaque Psoriasis
This trial is testing a new drug for plaque psoriasis in adolescents to see if it is safe and effective. The first part will test different doses to see what levels of the drug are safe and effective. The second part will test the long-term safety of the drug.
Monoclonal Antibodies
Tildrakizumab for Pediatric Psoriasis
This trial involves studying how a drug moves through and is processed by the bodies of children. It first examines older children and then younger children. The goal is to understand how the drug is absorbed, distributed, metabolized, and excreted in these age groups.
Monoclonal Antibodies
Tildrakizumab for Nail Psoriasis
This trial is testing Tildrakizumab, a medication that helps reduce inflammation, in patients with moderate to severe nail psoriasis. These patients often do not respond well to standard treatments. Tildrakizumab works by blocking a protein that causes inflammation, helping to calm the immune system and reduce symptoms. Tildrakizumab has been shown to be effective in improving skin manifestations as well as enhancing quality of life outcomes in patients with psoriasis.
Trials for Psoriatic Arthritis Patients
Behavioral Intervention
Intermittent Fasting Diet for Psoriasis and Psoriatic Arthritis
This trial is studying whether intermittent fasting can improve psoriasis & PsA disease severity & quality of life. It will look at clinical parameters, biometric measurements, & quality of life indices. Results will help determine the role of IMF & other diets in psoriasis & provide dietary recommendations.
Phase 3 Trials
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
Monoclonal Antibodies
Subcutaneous Guselkumab for Psoriasis
This trial is testing a medication called guselkumab to see if it is safe and effective for children and teenagers with chronic plaque psoriasis. The medication aims to reduce inflammation and slow down the rapid growth of skin cells. Guselkumab is the first IL-23 specific inhibitor to be approved for the treatment of plaque psoriasis and has shown excellent safety and efficacy in previous studies.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Plaque Psoriasis
This trial is testing a new drug for plaque psoriasis in adolescents to see if it is safe and effective. The first part will test different doses to see what levels of the drug are safe and effective. The second part will test the long-term safety of the drug.
Trials With No Placebo
Phosphodiesterase 4 (PDE4) Inhibitor
Long-Term Apremilast Use for Psoriasis
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
TENS for Psoriasis Injection Pain
This trial is testing whether TENS therapy can reduce pain during and after the injection of biological medications. 10-20 subjects will be recruited and will receive the injection in one thigh with and one without the use of TENS therapy.
View More Related Trials
Frequently Asked Questions
Introduction to psoriasis
What are the top hospitals conducting psoriasis research?
When it comes to advancing treatment options for psoriasis, several top hospitals are making remarkable strides. In East Windsor, New jersey, the Psoriasis Treatment Center takes the lead with six ongoing clinical trials dedicated to improving outcomes for individuals living with this chronic skin condition. Having initiated their first trial in 2015, this center has already accumulated an impressive total of 26 psoriasis studies over time. Meanwhile, in Boston's esteemed Brigham and Women's Hospital, researchers are actively conducting five trials focused on finding innovative solutions for psoriasis patients. Although they have a comparatively smaller number of all-time trials (five), their dedication to furthering knowledge about this condition since their first recorded trial in 2003 is commendable.
In Houston's Center for Clinical Studies, experts are currently engaged in four active psoriasis trials as part of their commitment to expanding treatment options for those affected by the condition. With a history spanning back to 2004 when they conducted their inaugural trial on psoriasis patients, this institution has amassed valuable insights from a total of 32 previous studies.
Further west lies San Francisco's University of California campus where professionals at UCSF are actively involved in four ongoing clinical trials targeting improved therapies specifically designed for people struggling with psoriasis. Despite having conducted only seven all-time trials since embarking on their pioneering study back in 2002; UCSF continues its pursuit towards unlocking answers vital to addressing this challenging dermatological disease.
Finally yet importantly at Santa Monica’s Clinical Science Institute—four active clinical tests focusing exclusively on new avenues that could alleviate symptoms experienced by those diagnosed withpsoriasishave been carried out ever since recording inception was madein2010.Furthermore,the institute boasts an astounding thirty-five completedtrialswhich underlinesits commitment towards advancing care and understanding surroundingthis complex condition
These leading hospitals highlight the collective efforts being made nationwide toward unraveling the mysteries of psoriasis and uncovering more effective treatments.Increasing our knowledge through ongoing research not only provides hope to those impacted by psoriasis but also contributes to a brighter future where individuals can live free from the burdens of this chronic skin condition.
Which are the best cities for psoriasis clinical trials?
When it comes to psoriasis clinical trials, several cities are at the forefront of research and development. Miami, Florida leads the way with 23 active trials investigating treatments such as BMS-986165, Tildrakizumab, and Brodalumab. Houston, Texas closely follows with 20 ongoing studies focused on innovative approaches like risankizumab and Guselkumab. New york City also offers significant opportunities for participation in psoriasis trials with 20 active studies exploring treatments like Nivolumab and risankizumab. Other cities making strides in psoriasis research include Birmingham, Alabama with 19 active trials and San Antonio, Texas with 18 ongoing studies. These cities provide individuals dealing with psoriasis access to cutting-edge clinical trials that could potentially revolutionize treatment options for this condition.
Which are the top treatments for psoriasis being explored in clinical trials?
Psoriasis treatment research is making strides with several promising options being explored in clinical trials. One standout contender is deucravacitinib, currently involved in four active trials for psoriasis since its introduction in 2021. Another significant player is guselkumab, which has garnered attention with four ongoing and 22 all-time psoriasis trials since 2013. Tildrakizumab also shows promise, participating in three active studies and boasting a total of 11 psoriasis trials since its listing in 2019. Additionally, risankizumab has two active and fifteen all-time psoriasis trials under its belt since first being listed back in 2014. With each trial bringing us closer to improved treatments, the future looks brighter for individuals living with psoriasis.
What are the most recent clinical trials for psoriasis?
Exciting advancements in psoriasis treatment are emerging from recent clinical trials. One notable development is the investigation of deucravacitinib, which has entered Phase 4 trials and shows promise as a potential therapy for individuals with psoriasis. Another phase 3 trial focuses on guselkumab, an innovative medication that may offer relief to those suffering from psoriasis. In addition, risankizumab, also in Phase 4 trials, holds potential as a novel treatment option for this chronic skin condition. Lastly, a lotion containing 0.01% halobetasol and 0.045% tazarotene has shown encouraging results in its Phase 4 trial as an effective solution for managing psoriasis symptoms. These studies bring renewed hope to the lives of people living with psoriasis by offering new avenues for improved management and quality of life.
What psoriasis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of psoriasis treatment. In June 2022, Janssen Research & Development successfully completed a trial investigating the potential of JNJ-77242113 for managing this chronic skin condition. Additionally, AnaptysBio wrapped up their Imsidolimab low dose study in April 2022 and Meiji Pharma USA Inc. concluded their ME3183 trial in March 2022. These advancements highlight the continuous efforts by researchers to find more effective therapies for individuals suffering from psoriasis.